Active substances
Human papillomavirus type 16 l1 protein + Human papillomavirus type 18 l1 protein
- SFDA 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CERVARIX VACCINE | 20,20 µg,µg | Suspension for injection · Intramuscular use | 1 Pre-filled syringe | SAR 266.25 | Biological · Prescription | GLAXO SAUDI ARABIA | Valid |
| CERVARIX VACCINE | 20 , 20 µg | Suspension for injection · Intramuscular use | 1 Injection Syringe | SAR 266.25 | Biological · Prescription | GLAXO SAUDI ARABIA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ADULT IMMUNIZATION; TRAVEL IMMUNIZATION
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.